Send to

Choose Destination
Turk Kardiyol Dern Ars. 2019 Oct;47(7):564-571. doi: 10.5543/tkda.2019.58399.

Serum galectin-3 level predicts early recurrence following successful direct-current cardioversion in persistent atrial fibrillation patients.

Author information

Department of Basic Medical Sciences, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey.
Department of Cardiology, Selçuk University Faculty of Medicine, Konya, Turkey.
Department of Cardiology, Dinar State Hospital, Afyonkarahisar, Turkey.
Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.



Atrial structural remodeling has been suggested to contribute to atrial fibrillation (AF) recurrence following direct-current cardioversion (DCCV). The role of several inflammatory and extracellular matrix turnover markers in AF recurrence following DCCV has been investigated. However, data on the impact of galectin-3, which is known to play a role in various fibrotic conditions, including cardiac fibrosis are lacking. The aim of this study was to demonstrate the predictive role of serum galectin-3 levels in AF recurrence following successful DCCV.


A total of 90 persistent AF patients who were sche-duled for DCCV were prospectively enrolled. Serum samples were assayed to determine pre-DCCV galectin-3 levels using the enzyme-linked immunosorbent assay method. Patients were followed up for 3 months for AF recurrence.


Of 90 persistent AF patients (mean age: 55.33±7.94 years; 53.33% male) who underwent successful DCCV, 28 (31.11%) experienced early AF recurrence within 3 months. Patients with AF recurrence had a greater left atrial volume index (LAVI) (33.35±2.45 mL/m2 vs. 29.21±3.08 mL/m2; p<0.001) and serum galectin-3 levels were higher (0.88 ng/mL [min-max: 0.52-1.32] vs. 0.60 ng/mL [min-max: 0.38-0.91]; p<0.001). In multivariate analysis, the number of DCCV attempts (hazard ratio [HR]: 1.879, 95% confidence interval [CI]: 1.052-3.355; p=0.033), LAVI (HR: 1.180, 95% CI: 1.028-1.354; p=0.018), and serum galectin-3 level (HR: 11.933, 95% CI: 1.220-116.701; p=0.033) were found to be independently associated with early AF recurrence following successful DCCV.


Circulating levels of galectin-3 may have an association with early AF recurrence following DCCV.

Free full text

Supplemental Content

Full text links

Icon for Kare Publishing
Loading ...
Support Center